drugset / Trial / NCT00358449
Intravenous Mepolizumab In Children With Eosinophilic Esophagitis
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab in pediatric subjects with eosinophilic esophagitis.
Timeline
- Start
- 2006-09-11
- Primary completion
- 2008-11-25
- Completion
- 2008-11-25
Publications
- Background Assa'ad AH, Gupta SK, Collins MH, Thomson M, Heath AT, Smith DA, Perschy TL, Jurgensen CH, Ortega HG, Aceves SS. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology. 2011 Nov;141(5):1593-604. doi: 10.1053/j.gastro.2011.07.044. Epub 2011 Aug 9.
- Wong ECL, Gleave AL, Marshall JK, Narula N. Predictors of histologic response to mepolizumab in pediatric eosinophilic esophagitis. Eur J Gastroenterol Hepatol. 2023 Oct 1;35(10):1131-1136. doi: 10.1097/MEG.0000000000002623. Epub 2023 Jul 31.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mepolizumab | Monoclonal antibody | 0.55 mg/kg | Intravenous |
| Subject | Mepolizumab | Monoclonal antibody | 2.5 mg/kg | Intravenous |
| Subject | Mepolizumab | Monoclonal antibody | 10 mg/kg | Intravenous |